Company news

Crinetics Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2023

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

September 19, 2023

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

September 9, 2023

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

July 30, 2023

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

June 20, 2023

Crinetics to Highlight Broad Pipeline at ENDO 2023

June 8, 2023

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 27, 2023

Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 9, 2023

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference

January 8, 2023

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

November 27, 2022

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 13, 2022

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

October 12, 2022

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

October 5, 2022

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

October 2, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2022

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

September 1, 2022

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 11, 2022

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

August 3, 2022

Crinetics Presents Clinical and Research Results at ENDO 2022

June 7, 2022

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

June 6, 2022

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

May 24, 2022

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

April 17, 2022

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

April 11, 2022

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

March 29, 2022

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

March 20, 2022

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

March 13, 2022

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

February 28, 2022

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

February 27, 2022

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

February 8, 2022

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

January 11, 2022

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

January 4, 2022

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 17, 2021

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

November 7, 2021

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 4, 2021

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 24, 2021

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 19, 2021

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

September 26, 2021

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

September 14, 2021

Crinetics Pharmaceuticals to Participate in September Investor Conferences

September 6, 2021

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

September 1, 2021

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 9, 2021

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

August 9, 2021

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

July 28, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.